Hoffman-La Roche Secures 1-Year Extension for Bitopertin Drug Patent
December 11, 2025
December 11, 2025
WASHINGTON, Dec. 11 (TNSFR) -- Hoffman-La Roche Inc., Little Falls, New Jersey, has been granted a one-year interim extension by the U.S. Department of Commerce Patent and Trademark Office for its patent, which protects the human drug product Bitopertin oral tablets, allowing the patent term to extend beyond its original expiration date of Dec. 17, 2025.
The extension was sought through a timely application filed by the company on Dec. 1, 2025. This action falls under 35 U.S.C. 156( . . .
The extension was sought through a timely application filed by the company on Dec. 1, 2025. This action falls under 35 U.S.C. 156( . . .